Lynne Poole

Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib.

A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib.

Journal: Future oncology (London, England)

Published: July 16, 2026

Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 11, 2025

ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials.

ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 19, 2024

Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

Journal: Targeted oncology

Published: January 15, 2024

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

Journal: The New England journal of medicine

Published: June 05, 2023

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 03, 2022

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 16, 2020

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.

Journal: The Lancet. Oncology

Published: March 18, 2019

Managing acute central nervous system infections in the UK adult intensive care unit in the wake of UK encephalitis guidelines.

Managing acute central nervous system infections in the UK adult intensive care unit in the wake of UK encephalitis guidelines.

Journal: Journal of the Intensive Care Society

Published: November 01, 2015

Analysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients.

Analysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients.

Journal: International journal of nephrology and renovascular disease

Published: July 22, 2014

Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients.

Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients.

Journal: BMC nephrology

Published: November 05, 2012

Lanthanum carbonate reduces urine phosphorus excretion: evidence of high-capacity phosphate binding.

Lanthanum carbonate reduces urine phosphorus excretion: evidence of high-capacity phosphate binding.

Journal: Renal failure

Published: January 19, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026